Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has announced the receipt of a US$100 million option payment from Takeda. This payment is part of an Exclusive Option Agreement that grants Takeda the opportunity to license the potentially groundbreaking BCR-ABL inhibitor, olverembatinib. – Substantial Financial Commitment: […]
Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab (TAK-079) in individuals with persistent or chronic primary immune thrombocytopenia (ITP). The study, known as TAK-079-1004 (NCT04278924), explored the impact of three different doses of subcutaneous mezagitamab versus placebo, administered […]
Takeda has announced a significant advancement in the treatment of Hereditary Angioedema (HAE), with the European Commission’s approval of TAKHZYRO (lanadelumab) for routine prevention in patients aged 2 years and older. This approval marks the first long-term prophylactic HAE treatment available in the European Economic Area for patients under six years of age, broadening the […]
Takeda has achieved a monumental milestone in rare disease therapy with the U.S. Food and Drug Administration’s approval of ADZYNMA (ADAMTS13, recombinant-krhn) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP). This approval marks ADZYNMA as the first and only FDA-approved recombinant ADAMTS13 protein, addressing a critical unmet medical need in people with cTTP by […]
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its primary endpoint, the study confirmed that TAK-279 improved symptoms significantly better than a placebo at 12 weeks. This news supports TAK-279’s potential as a robust oral treatment for psoriatic arthritis […]
Takeda’s pioneering Phase 2 trial of TAK-994, a potential treatment for narcolepsy type 1 (NT1), came to an abrupt halt due to hepatotoxicity concerns, according to a report published in The New England Journal of Medicine. This marks the termination of the TAK-994 program, despite the promising results of the oral orexin agonist on narcolepsy […]
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). This makes TAK-755 the only recombinant ADAMTS13 protein under development, targeting an unmet medical need in TTP patients by replacing the missing or […]
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under the licensing agreement, the Japanese pharmaceutical company will further develop and market the VEGFR1/2/3 tyrosine kinase inhibitor in all indications and territories outside of mainland China, Hong Kong, and Macau. […]